Thus, our data illustrate an essential function for RRP9 to promote gemcitabine resistance, and indicate that targeting RRP9 through AKT could propose a new therapeutic strategy to sensitize PC cells to gemcitabine. Here, RRP9 is linked to pachyonychia congenita.